SLC52A2 and renal tubular dysgenesis of genetic origin: Collectively, our results indicate that AAV9-SLC52A2 vector rescues the neural phenotype in motoneurons derived from RTD Type 2 patient iPSCs, which warrants further in vitro as well as in vivo studies to develop gene therapy as a potential clinical treatment for these patients.